Results 41 to 50 of about 66,826 (280)

Can adalimumab prevent from acute effects of lipopolysaccharide induced renal injury in rats? [PDF]

Acta Cirúrgica Brasileira
Purpose: Lipopolysaccharides is well-known in the acute renal injury process. It causes widespread activation of inflammatory cascades. Tumor necrosis factor (TNF)-α and interleukin (Il)-6 are essential proinflammatory cytokines that can induce the ...
Nuket Özkavruk Eliyatkın, Akif İşlek, Selim Durmaz, Fevzi Ayyıldız, Ömer Rahman   +4 more
doaj   +1 more source

New insights into the impact of neuro-inflammation in rheumatoid arthritis. [PDF]

, 2014
Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint and systemic inflammation.
Akasbi, Alten, Askling, Axford, Barrick, Bean, Bekkelund, Bongartz, Burmester, Burmester, Capellino, Cheng, Chiu, Chou, Combs, De Almeida, De Rycke, Detrait, Diamond, Doran, Doran, Emmer, Fayed, Feldmann, Firestein, Franklyn A. Howe, Germano, Gregersen, Gussew, Hamed, Harris, Ho, Hull, Hunter, Inan, Jacobs, Kaltsonoudis, Keane, Keystone, King, Klareskog, Lauvsnes, Lee, Leombruno, Lipsky, Listing, MacGregor, Mahdi, Malaviya, Markenson, McInnes, Medeiros, Mellor, Meseguer, Mikuls, Morris, Nadeau, Ni Mhuircheartaigh, Nicholas R. Fuggle, Nidhi Sofat, Nishioku, Norheim, O'Callaghan, Ogawa, Panayi, Parks, Rachel L. Allen, Ramiro, Rech, Rosenblum, Salliot, Salmon-Ceron, Scher, Schoels, Schweinhardt, Scott, Senaldi, Serrats, Skelly, Smolen, Sokka, Steens, Strangfeld, Symmons, Taylor, Teeling, Thomson, Tracey, Tubach, Upadhyay, van der Woude, van Heemst, van Vollenhoven, Vincent, Wallis, Wartolowska, Wegner, Wellcome Trust Case Control Consortium., Wendler, Weyand, Wolfe, Woolf, Zivadinov   +102 more
core   +2 more sources

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources

Prevalence of Systemic Lupus Erythematosus in Australia, 2010–2022: A Population‐Based Study Using Linked National Administrative Health Data

Arthritis Care &Research, Accepted Article.
Objectives Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition, with widely varying global prevalence estimates. Frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the US or UK at 19‐39 per 100,000 as opposed to 65‐97 per 100,000.
Lucinda Roper, Rachel Black, Joanna Tieu, Winnie Chen, Matthew Parker, Catherine Hill, Natasha Nassar, Mandana Nikpour   +7 more
wiley   +1 more source

Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy

Bioengineering & Translational Medicine
Adalimumab (Humira) represents a major advance in rheumatoid arthritis (RA) therapy. However, with long‐term administration of Adalimumab, anti‐idiotypic antibody (anti‐Id Ab) accelerates the Adalimumab clearance rate and reduces the therapeutic effect ...
Bo‐Cheng Huang, Yu‐Tung Chen, Yun‐Chi Lu, Kai‐Wen Ho, Shih‐Ting Hong, Tzu‐Yi Liao, I‐Hsuan Wu, En‐Shuo Liu, Jun‐Min Liao, Fang‐Ming Chen, Chia‐Ching Li, Chih‐Hung Chuang, Chiao‐Yun Chen, Tian‐Lu Cheng   +13 more
doaj   +1 more source

Adalimumab

Annales de Dermatologie et de Vénéréologie, 2019
  +10 more sources

Adalimumab: A key element in the treatment strategy for immune-mediated inflammatory diseases: A review [PDF]

Consilium Medicum
Adalimumab is a biological drug effectively used in the treatment of several immune-mediated inflammatory diseases, including ankylosing spondylitis, juvenile idiopathic arthritis, and psoriasis.
Mariam A. Gilavian, Daria V. Trunova, Anastasia V. Ustinova, Anna M. Sukhanova   +3 more
doaj   +1 more source

The efficacy of adalimumab in treating patients with central multifocal choroiditis

American Journal of Ophthalmology Case Reports, 2020
Purpose: To evaluate the efficacy of adalimumab in patients with central multifocal choroiditis (cMFC) refractory to conventional corticosteroid-sparing immunomodulatory agents (IMT). Methods: Medical records were reviewed from all patients with cMFC and
Evianne L. de Groot, Jeannette Ossewaarde - van Norel, Lintje Ho, Ninette H. ten Dam - van Loon, Joke H. de Boer   +4 more
doaj   +1 more source

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity [PDF]

, 2010
Introduction: This study is based on the results from a Belgian expanded access program in which patients with active refractory and erosive rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab in combination with methotrexate.
Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, De Keyser, Filip   +3 more
core   +1 more source